EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Hepatocyte growth factor for walking performance in peripheral artery disease

Mary M McDermott, Robert Sufit, Kathryn J Domanchuk, Nicholas J Volpe, Kate Kosmac, Charlotte A Peterson, Lihui Zhao, Lu Tian, Dongxue Zhang, Shujun Xu, Ahmed Ismaeel, Luigi Ferrucci und 9 weitere

Journal of Vascular Surgery · 2025

DOI: 10.1016/j.jvs.2024.12.124 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Vascular Surgery, 2025. Verfasst von Mary M McDermott und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Preventive Medicine, Northwestern Un…. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Muscle, Skeletal, Walking, Hepatocyte Growth Factor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: VM202 is a plasmid encoding two isoforms of hepatocyte growth factor. In preclinical studies, hepatocyte growth factor stimulated angiogenesis and muscle regeneration. This preliminary clinical trial tested the hypothesis that VM202 injections in gastrocnemius muscle would improve walking performance in people with mild to moderate and symptomatic lower extremity peripheral artery disease (PAD). METHODS: In a double-blind clinical trial, patients with PAD were randomized to gastrocnemius muscle injections of either 4 mg of VM202 or placebo every 14 days for four treatments. The primary outcome was 6-month change in 6-minute walk distance. Secondary outcomes included 3-month change in treadmill walking time and gastrocnemius muscle biopsy measures. In this preliminary trial, statistical significance was prespecified as a one-sided P value of less than .10. RESULTS: Thirty-nine participants with PAD (64.1% Black, 28.2% female) were randomized. Adjusting for age, race, smoking, and baseline performance, VM202 did not improve 6-minute walk at 6-month follow-up, compared with placebo (-13.5 m; 90% confidence interval [CI], -38.5 to +∞). At the 3-month follow-up, VM202 improved the maximum treadmill walking time (+2.38 minutes; 90% CI, +1.08 to +∞; P = .014) and increased central nuclei abundance in gastrocnemius muscle (+5.86; 90% CI, +0.37 to +∞; P = .088), compared with placebo. VM202 did not significantly improve pain-free walking distance (difference, +0.30 minutes; 90% CI, -1.10 to +∞; P = .39), calf muscle perfusion (difference, +1.80 mL/min per 100 g tissue; 90% CI, -3.80 to +∞; P = .33), or the Walking Impairment Questionnaire distance score (difference, +2.02; 90% CI, -8.11 to +∞; P = .40). In post hoc analyses, VM202 significantly improved 6-minute walk in PAD participants with diabetes mellitus at 6-month follow-up (+34.19; 90% CI, 4.04 to +∞; P = .075), but had no effect in people without diabetes (interaction P = .079). CONCLUSIONS: These data do not support gastrocnemius injections of VM202 to improve 6-minute walk in PAD. Secondary outcomes suggested potential benefit of VM202 on skeletal muscle measures and treadmill walking, whereas post hoc analyses suggested benefit in PAD participants with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseaseMuscle, SkeletalWalkingHepatocyte Growth FactorExercise ToleranceGenetic TherapyIntermittent ClaudicationHumansFemaleMaleDouble-Blind MethodAgedMiddle AgedTime FactorsTreatment OutcomeWalk TestRecovery of FunctionInjections, Intramuscular

Stichwörter der Autor:innen

6-Minute walkClinical trialGene therapyIntermittent claudicationPeripheral artery diseasemobility

Substanzen

Hepatocyte Growth FactorHGF protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address:…
  • Northwestern University Feinberg School of Medicine, Department of Neurology, Chicago, IL.
  • Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Department of Physical Therapy, Augusta University, Augusta, GA.
  • Center for Muscle Biology, University of Kentucky, Lexington, KY.

Förderung

  • NIA NIH HHS

Zitieren

APA

McDermott, M. M., Sufit, R., Domanchuk, K. J., Volpe, N. J., Kosmac, K., Peterson, C. A., Zhao, L., Tian, L., Zhang, D., Xu, S., Ismaeel, A., Ferrucci, L., Parekh, N. D., Lloyd-Jones, D., Kramer, C. M., Leeuwenburgh, C., Ho, K., Criqui, M. H., Polonsky, T., …, & Kibbe, M. R. (2025). Hepatocyte growth factor for walking performance in peripheral artery disease. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2024.12.124

Vancouver

McDermott MM, Sufit R, Domanchuk KJ, Volpe NJ, Kosmac K, Peterson CA, et al. Hepatocyte growth factor for walking performance in peripheral artery disease. Journal of Vascular Surgery. 2025. doi:10.1016/j.jvs.2024.12.124

BibTeX
@article{McDermott2025,
  author = {McDermott, Mary M and Sufit, Robert and Domanchuk, Kathryn J and Volpe, Nicholas J and Kosmac, Kate and Peterson, Charlotte A and Zhao, Lihui and Tian, Lu and Zhang, Dongxue and Xu, Shujun and Ismaeel, Ahmed and Ferrucci, Luigi and Parekh, Nishant D and Lloyd-Jones, Donald and Kramer, Christopher M and Leeuwenburgh, Christiaan and Ho, Karen and Criqui, Michael H and Polonsky, Tamar and Guralnik, Jack M and Kibbe, Melina R},
  title = {Hepatocyte growth factor for walking performance in peripheral artery disease},
  journal = {Journal of Vascular Surgery},
  year = {2025},
  doi = {10.1016/j.jvs.2024.12.124}
}
Kostenlos starten →